Related Experiment Video

Updated: Apr 4, 2026

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

1.8K

Platelet count and associated morbidities in VLBW infants with pharmacologically treated patent ductus arteriosus

Daniel P Murphy1,2, Henry C Lee3,4, Kurlen S E Payton5

  • 1a Department of Pediatrics, Division of Neonatology , Los Angeles County Harbor-UCLA Medical Center , Torrance , CA , USA .

The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
|September 15, 2015
PubMed

Insights

Platelet count did not significantly impact patent ductus arteriosus (PDA) closure or the risk of serious morbidities like IVH and NEC in preterm infants receiving medical treatment for PDA.

Area of Science:

  • Neonatal Medicine
  • Pediatric Cardiology
  • Hematology

Background:

  • Patent ductus arteriosus (PDA) is common in preterm infants, often requiring medical management.
  • The role of pretreatment platelet count in outcomes for pharmacologically treated PDA is not well-defined.
  • Investigating platelet count's association with morbidities like IVH and NEC is crucial for risk stratification.

Purpose of the Study:

  • To characterize PDA diagnosis and pretreatment platelet count distribution in infants weighing ≤1500g.
  • To assess the relationship between platelet count and serious morbidities in pharmacologically managed PDA.
  • To evaluate the impact of platelet count on PDA closure rates.

Main Methods:

  • Retrospective, observational study across 40 hospitals.
  • Data collected on PDA diagnosis, pretreatment platelet count, and clinical outcomes (IVH, NEC, PDA closure).
  • Chi-square test used for statistical comparison of outcomes across different platelet count groups.

Main Results:

  • 311 infants with medically treated PDA were analyzed, with platelet counts categorized.
  • No significant differences in the incidence or grade of intraventricular hemorrhage (IVH) across platelet groups.
  • Rates of necrotizing enterocolitis (NEC) and PDA closure showed no significant association with pretreatment platelet count.

Conclusions:

  • Pretreatment platelet count is not a significant factor influencing PDA closure in infants treated with medication.
  • Platelet count did not statistically predict the development of IVH or NEC in this cohort.
  • Findings suggest platelet count has a limited role in predicting outcomes for pharmacologically managed PDA.
Abstract

Keywords:
COX1 inhibitorintraventricular hemorrhageligationnecrotizing enterocolitispatent ductus arteriosusthrombocytopeniavery low birth weight

More Related Videos

A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis06:19

A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis

Published on: January 7, 2018

11.0K
Author Spotlight: Establishment and Confirmation of a Postnatal Right Ventricular Volume Overload Mouse Model06:04

Author Spotlight: Establishment and Confirmation of a Postnatal Right Ventricular Volume Overload Mouse Model

Published on: June 9, 2023

1.6K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
474
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.7K
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
782